Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 112
1.
Biochemistry (Mosc) ; 89(3): 562-573, 2024 Mar.
Article En | MEDLINE | ID: mdl-38648773

The contents of homocysteine (HCy), cyanocobalamin (vitamin B12), folic acid (vitamin B9), and pyridoxine (vitamin B6) were analyzed and the genotypes of the main gene polymorphisms associated with folate metabolism (C677T and A1298C of the MTHFR gene, A2756G of the MTR gene and A66G of the MTRR gene) were determined in children at the onset of multiple sclerosis (MS) (with disease duration of no more than six months), healthy children under 18 years (control group), healthy adults without neurological pathology, adult patients with MS at the onset of disease, and adult patients with long-term MS. A significant increase in the HCy levels was found in children at the MS onset compared to healthy children of the corresponding age. It was established that the content of HCy in children has a high predictive value. At the same time, an increase in the HCy levels was not accompanied by the deficiency of vitamins B6, B9, and B12 in the blood. The lack of correlation between the laboratory signs of vitamin deficiency and HCy levels may be due to the polymorphic variants of folate cycle genes. An increased HCy level should be considered as a marker of functional disorders of folate metabolism accompanying the development of pathological process in pediatric MS. Our finding can be used to develop new approaches to the prevention of demyelination in children and treatment of pediatric MS.


5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase , Folic Acid , Homocysteine , Methylenetetrahydrofolate Reductase (NADPH2) , Multiple Sclerosis , Humans , Homocysteine/blood , Homocysteine/metabolism , Multiple Sclerosis/blood , Multiple Sclerosis/genetics , Multiple Sclerosis/metabolism , Folic Acid/blood , Folic Acid/metabolism , Female , Male , Child , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Methylenetetrahydrofolate Reductase (NADPH2)/deficiency , Methylenetetrahydrofolate Reductase (NADPH2)/metabolism , 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase/genetics , 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase/metabolism , Adult , Adolescent , Vitamin B Deficiency/complications , Vitamin B Deficiency/metabolism , Vitamin B Deficiency/blood , Ferredoxin-NADP Reductase/genetics , Ferredoxin-NADP Reductase/metabolism , Vitamin B 12/blood , Vitamin B 12/metabolism , Age of Onset
2.
J Biol Inorg Chem ; 29(3): 375-383, 2024 Apr.
Article En | MEDLINE | ID: mdl-38289478

Previous studies reported that Pb exposure causes a negative association with delta-aminolevulinic acid dehydratase activity (δ-ALAD), but the impact of Pb exposure (dose and time), B vitamin deficiencies, and lifestyle factors needs to be explored. In this study, the impact of Pb exposure, B vitamin deficiencies, and lifestyle factors on δ-ALAD activity among workers exposed to Pb from the Pb-recycling process was evaluated. Blood lead levels (BLLs), B vitamins (B6, B9, and B12), hematological factors (Hb% and HCT), lifestyle factors, and δ-ALAD activity was assessed in 170 male Pb-exposed workers engaged in the Pb recycling process. BLLs are estimated using the ICP-OES method. B vitamins in serum samples from workers were determined using the ELISA method. The δ-ALAD activity in whole blood samples was determined using the spectrophotometer method. The lifestyle factors were collected using a standard questionnaire. The δ-ALAD activity was significantly decreased in workers with the habits of alcohol use, tobacco consumption, hematocrit < 41%, mild and moderate categories of anemia, vitamin B6 and B12 deficiency, and BLL categories of 10-30, 30-50, and > 50 µg/dL. Multiple regression analysis revealed that the independent variables of alcohol consumption (ß = - 0.170; P = 0.025), BLLs (ß = - 0.589; P = 0.001) and Hb% (ß = 0.183; P = 0.001) significantly influenced the δ-ALAD activity with 44.2% (R2 = 0.442). Among the workers exposed to Pb from the Pb recycling plant, δ-ALAD activity was considerably reduced by Pb exposure, B vitamin deficiency, hematological parameters, and lifestyle factors.


Lead , Occupational Exposure , Porphobilinogen Synthase , Humans , Porphobilinogen Synthase/metabolism , Porphobilinogen Synthase/blood , Male , Lead/blood , Adult , Occupational Exposure/adverse effects , Occupational Exposure/analysis , Vitamin B Deficiency/blood , Recycling , Middle Aged , Vitamin B Complex/blood
3.
Br J Cancer ; 124(12): 1997-2003, 2021 06.
Article En | MEDLINE | ID: mdl-33837300

BACKGROUND: Folate, vitamin B6 and vitamin B12 have been associated with digestive system cancers. We conducted a two-sample Mendelian randomisation study to assess the causality of these associations. METHODS: Two, one and 14 independent single nucleotide polymorphisms associated with serum folate, vitamin B6 and vitamin B12 at the genome-wide significance threshold were selected as genetic instruments. Summary-level data for the associations of the vitamin-associated genetic variants with cancer were obtained from the UK Biobank study including 367,561 individuals and FinnGen consortium comprising up to 176,899 participants. RESULTS: Genetically predicted folate and vitamin B6 concentrations were not associated with overall cancer, overall digestive system cancer or oesophageal, gastric, colorectal or pancreatic cancer. Genetically predicted vitamin B12 concentrations were positively associated with overall digestive system cancer (ORSD, 1.12; 95% CI 1.04, 1.21, p = 0.003) and colorectal cancer (ORSD 1.16; 95% CI 1.06, 1.26, p = 0.001) in UK Biobank. Results for colorectal cancer were consistent in FinnGen and the combined ORSD was 1.16 (95% CI 1.08, 1.25, p < 0.001). There was no association of genetically predicted vitamin B12 with any other site-specific digestive system cancers or overall cancer. CONCLUSIONS: These results provide evidence to suggest that elevated serum vitamin B12 concentrations are associated with colorectal cancer.


Digestive System Neoplasms/blood , Digestive System Neoplasms/epidemiology , Polymorphism, Single Nucleotide , Vitamin B Complex/blood , Adult , Anemia, Pernicious/blood , Anemia, Pernicious/epidemiology , Anemia, Pernicious/genetics , Case-Control Studies , Digestive System Neoplasms/diagnosis , Digestive System Neoplasms/genetics , Female , Folic Acid/blood , Folic Acid/genetics , Genetic Association Studies , Genetic Predisposition to Disease , Genetic Testing , Humans , Male , Mendelian Randomization Analysis , Risk Factors , Sweden/epidemiology , United Kingdom/epidemiology , Vitamin B 12/blood , Vitamin B 12/genetics , Vitamin B 6/blood , Vitamin B 6/genetics , Vitamin B Complex/genetics , Vitamin B Deficiency/blood , Vitamin B Deficiency/epidemiology , Vitamin B Deficiency/genetics
4.
J Nutr ; 150(Suppl 1): 2538S-2547S, 2020 10 01.
Article En | MEDLINE | ID: mdl-33000166

The central position of methionine (Met) in protein metabolism indicates the importance of this essential amino acid for growth and maintenance of lean body mass. Therefore, Met might be a tempting candidate for supplementation. However, because Met is also the precursor of homocysteine (Hcy), a deficient intake of B vitamins or excessive intake of Met may result in hyperhomocysteinemia (HHcy), which is a risk factor for cardiovascular disease. This review discusses the evidence generated in preclinical and clinical studies on the importance and potentially harmful effects of Met supplementation and elaborates on potential clinical applications of supplemental Met with reference to clinical studies performed over the past 20 y. Recently acquired knowledge about the NOAEL (no observed adverse effect level) of 46.3 mg · kg-1 · d-1 and the LOAEL (lowest observed adverse effect level) of 91 mg · kg-1 · d-1 of supplemented Met will guide the design of future studies to further establish the role of Met as a potential (safe) candidate for nutritional supplementation in clinical applications.


Body Fluid Compartments/metabolism , Cardiovascular Diseases/etiology , Dietary Supplements , Homocysteine/metabolism , Hyperhomocysteinemia/etiology , Methionine , Vitamin B Deficiency/complications , Animals , Cardiovascular Diseases/metabolism , Female , Humans , Hyperhomocysteinemia/metabolism , Male , Methionine/adverse effects , Methionine/metabolism , Methionine/pharmacology , Methionine/therapeutic use , Proteins/metabolism , Vitamin B Complex/blood , Vitamin B Deficiency/blood
5.
Pain Physician ; 23(1): E41-E49, 2020 01.
Article En | MEDLINE | ID: mdl-32013287

BACKGROUND: Because of the subjective nature of current pain assessments, limited efficacy of treatment options and risks associated with opioid abuse and diversion, the need for objective data to assist with chronic pain management has never been greater. Successful identification of mechanistic biomarkers would not only improve our understanding and ability to accurately diagnose pain disorders but would also facilitate the development of disease-modifying pain drugs. OBJECTIVES: The objective of this study was to determine and evaluate the prevalence of abnormal biomarker findings in a population of patients with chronic pain. STUDY DESIGN: Retrospective, observational study. SETTING: Data analysis of biomarker test results was performed at a single industry site (Ethos Research & Development, Newport, KY) from clinical samples collected and analyzed from July to December 2018. METHODS: A novel, pain-specific biomarker test panel that evaluates biomarkers of systemic inflammation, oxidative stress, neurotransmitter turnover, and micronutrient status was employed to determine the prevalence of abnormal findings in 17,834 unique patient samples analyzed at a national reference laboratory (Ethos Laboratories, Newport, KY). Patient biomarker results were considered abnormal if they were outside of the 95% confidence interval reference ranges established using a healthy population of donors who had no history of chronic pain or opioid use. RESULTS: A total of 77% of patients with chronic pain exhibited at least one abnormal biomarker result (n = 13,765). The most common abnormal biomarker finding was elevated quinolinic acid, which was observed in 29% of patients (n = 5,107). Elevated pyroglutamate, indicative of glutathione depletion, was observed in 19% of patients (n = 3,314). Elevated xanthurenic acid, indicative of vitamin B6 insufficiency, was observed in 17% of patients (3,025). Elevated levels of the acrolein metabolite 3-hydroxypropyl mercapturic acid were observed in 21% of patients (n = 3,667). Elevated methylmalonic acid, indicative of a vitamin B12 deficiency, was observed in 10% of patients (n = 1,827), whereas abnormally low levels of neurotransmitter metabolites were observed in 8% of patients (n = 1,456). LIMITATIONS: Medications and/or conditions other than those associated with chronic pain were not evaluated as potential causes of abnormal biomarker findings. CONCLUSIONS: A novel biomarker assay that measures objective correlates to the neurobiological processes underlying chronic pain reveals a high prevalence of atypical biochemistry in a population of patients with pain. Abnormal biomarker findings presented here provide objective support for the role of cytokine-mediated inflammation, oxidative stress, abnormally low production of neurotransmitters, and micronutrient deficiencies in the development or worsening of chronic pain. This unique panel of functional pain biomarkers provides practitioners with novel, objective insight into the underlying causes of pain, which will pave the way for truly personalized pain medicine. Correcting abnormal biomarker findings with targeted, nonopioid therapies to improve patient function and alleviate pain potentially could lessen the opioid burden and drastically reduce health care costs. KEY WORDS: Biomarker, pain, inflamation, oxidative stress, neurotransmitter, micronutrient deficiency, Kynurenine Pathway.


Chronic Pain/blood , Chronic Pain/diagnosis , Pain Measurement/methods , Analgesics, Opioid/therapeutic use , Biomarkers/blood , Chronic Pain/drug therapy , Female , Humans , Male , Prevalence , Retrospective Studies , Vitamin B Complex/blood , Vitamin B Deficiency/blood , Vitamin B Deficiency/diagnosis , Vitamin B Deficiency/drug therapy
6.
Osteoporos Int ; 30(3): 593-599, 2019 Mar.
Article En | MEDLINE | ID: mdl-30483849

The associations of multiple vitamin deficiencies on incident fractures were uncertain, the relationships between serum vitamin markers and incident bone fractures were investigated in Japanese postmenopausal women. The number of deficiencies was additively associated with incident fracture after adjustment for possible confounding factors including the treatment of osteoporosis. INTRODUCTION: To evaluate the associations of multiple vitamin deficiencies on incident fractures, the relationships between serum vitamin markers and incident bone fractures were investigated in Japanese postmenopausal women. METHODS: This analysis used a subset of the ongoing cohort maintained by a primary care institution. Inclusion criteria of the present study were postmenopausal women aged ≥ 50 years, without vitamin supplementation and secondary osteoporosis. Baseline serum concentrations of 25-hydroxyvitamin D (25(OH)D), undercarboxylated osteocalcin (ucOC), and homocysteine (Hcy) were measured to assess vitamin D, vitamin K, and vitamin B, respectively. Since 25(OH) D positively relates to vitamin D, ucOC and Hcy negatively relate to vitamin K and vitamin B nutrients, respectively, the subjects with lower (25(OH)D) or higher (ucOC or Hcy) values than each median value was defined as subjects with the corresponding vitamin deficiency. Subjects were divided into four groups according to the number of deficiency: no deficiency, single deficiency, double deficiencies, and triple deficiencies. Relationships between the vitamin deficiencies and incident fractures were evaluated by Cox regression analysis. RESULTS: A total of 889 subjects were included in this analysis; their mean and SD age was 68.3 ± 9.5 years, and the follow-up period was 6.3 ± 5.1 years. The numbers of subjects in the four groups were 139 (15.6%), 304 (34.2%), 316 (35.5%), and 130 (14.6%) for the groups with no, single, double, and triple deficiencies, respectively. Incident fractures were observed in 264 subjects (29.7%) during the observation period. The number of deficiencies was significantly associated with incident fracture (hazard ratio 1.25, 95% confidence interval 1.04-1.50, P = 0.018) after adjustment for possible confounding factors including the treatment of osteoporosis. CONCLUSION: Accumulation of vitamin deficiencies was related to incident fractures.


Avitaminosis/complications , Osteoporosis, Postmenopausal/etiology , Osteoporotic Fractures/etiology , Absorptiometry, Photon/methods , Aged , Avitaminosis/blood , Avitaminosis/epidemiology , Bone Density/physiology , Female , Homocysteine/blood , Humans , Incidence , Japan/epidemiology , Middle Aged , Osteocalcin/blood , Osteoporosis, Postmenopausal/blood , Osteoporosis, Postmenopausal/epidemiology , Osteoporotic Fractures/blood , Osteoporotic Fractures/epidemiology , Risk Factors , Vitamin B Deficiency/blood , Vitamin B Deficiency/complications , Vitamin B Deficiency/epidemiology , Vitamin D/analogs & derivatives , Vitamin D/blood , Vitamin D Deficiency/blood , Vitamin D Deficiency/complications , Vitamin D Deficiency/epidemiology , Vitamin K Deficiency/blood , Vitamin K Deficiency/complications , Vitamin K Deficiency/epidemiology
7.
Vopr Pitan ; 87(1): 63-71, 2018.
Article Ru | MEDLINE | ID: mdl-30592843

The article presents the results of the study aimed at confirmation of the effectiveness of the rats' adaptive potential reduction under conditions of cadmium salt toxic effects. The 65-days experiment was conducted in male and female Wistar rats. Animals were divided into 6 groups of 3 control and 3 experimental, 30 males and females in each. In total 360 rats were used in the experiment (180 females and 180 males). Rats of the 1st control group received a diet with optimal (75% of the standard semisyntethic diet content) dosage of vitamins B1, B2, B3, B6 and mineral substances, Fe3+ and Mg2+, the rats of the 2nd and the 3rd control group - diets with marginal (30% for males and 28% for females) and submarginal (19% for males and 18% for females) doses of essential micronutrients. Animals of the 1-3th experimental groups received Cd2+ on the background of optimal, marginal and submarginal providing of essential micronutrients. The hematological, biochemical and morphological parameters and the antioxidant status of rats have been studied. The obtained results allowed to identify patterns of cadmium toxic effect strengthen on the background of essential nutrients reducing (in the row from optimal to submarginal). These changes showed erythrocyte and platelet blood profiles, and a set of indicators of the antioxidant defense system and lipid peroxidation of blood and liver. Thus, the activity of erythrocyte antioxidant enzymes - glutathione reductase, glutathione peroxidase, catalase and superoxide dismutase in rats of the 1st experimental group were on average by 23% higher than in animals of the 1st control group, the rats of the 2nd and the 3rd experimental groups by 62 and 67% higher, respectively. The content of lipid peroxidation products in blood and liver of male and female rats showed a similar trend: an increase by 5% in the 1st experimental group by 9 and 25% in the 2nd and 3rd experimental groups respectively. Thus, the modification of the diets' vitamin-mineral composition may be used as a model of adaptive potential reduction in rats in the toxicological research of objects with unknown toxicity, in particular novel food products.


Antioxidants/metabolism , Cadmium Poisoning/blood , Minerals/blood , Sex Characteristics , Vitamin B Deficiency/blood , Animals , Disease Models, Animal , Female , Iron/blood , Magnesium/blood , Male , Oxidoreductases/blood , Rats , Rats, Wistar , Vitamin B Complex/blood
8.
Nutr Res Rev ; 31(2): 204-224, 2018 12.
Article En | MEDLINE | ID: mdl-29739477

The possible roles of selected B vitamins in the development and progression of sarcopenia are reviewed. Age-related declines in muscle mass and function are associated with huge and increasing costs to healthcare providers. Falls and loss of mobility and independence due to declining muscle mass/function are associated with poor clinical outcomes and their prevention and management are attractive research targets. Nutritional status appears a key modifiable and affordable intervention. There is emerging evidence of sarcopenia being the result not only of diminished anabolic activity but also of declining neurological integrity in older age, which is emerging as an important aspect of the development of age-related decline in muscle mass/function. In this connection, several B vitamins can be viewed as not only cofactors in muscle synthetic processes, but also as neurotrophic agents with involvements in both bioenergetic and trophic pathways. The B vitamins thus selected are examined with respect to their relevance to multiple aspects of neuromuscular function and evidence is considered that requirements, intakes or absorption may be altered in the elderly. In addition, the evidence base for recommended intakes (UK recommended daily allowance) is examined with particular reference to original datasets and their relevance to older individuals. It is possible that inconsistencies in the literature with respect to the nutritional management of sarcopenia may, in part at least, be the result of compromised micronutrient status in some study participants. It is suggested that in order, for example, for intervention with amino acids to be successful, underlying micronutrient deficiencies must first be addressed/eliminated.


Diet , Muscle, Skeletal/drug effects , Nutritional Requirements , Nutritional Status , Sarcopenia/etiology , Vitamin B Complex/blood , Vitamin B Deficiency/complications , Aged , Humans , Muscle, Skeletal/innervation , Muscle, Skeletal/pathology , Neuroprotective Agents/blood , Neuroprotective Agents/metabolism , Neuroprotective Agents/therapeutic use , Nutrition Policy , Sarcopenia/blood , Sarcopenia/prevention & control , United Kingdom , Vitamin B Complex/therapeutic use , Vitamin B Deficiency/blood , Vitamin B Deficiency/drug therapy
10.
J Nutr ; 147(9): 1658-1668, 2017 09.
Article En | MEDLINE | ID: mdl-28794210

Background: An elevated circulating cystathionine concentration, which arises in part from insufficiencies of vitamin B-6, B-12, or folate, has been shown to be associated with cardiovascular disease (CVD) risk. Hydrogen sulfide (H2S) is a gasotransmitter involved in vasodilation, neuromodulation, and inflammation. Most endogenously produced H2S is formed by pyridoxal phosphate (PLP)-dependent enzymes by noncanonical reactions of the transsulfuration pathway that yield H2S concurrently form lanthionine and homolanthionine. Thus, plasma lanthionine and homolanthionine concentrations can provide relative information about H2S production in vivo.Objective: To determine the metabolic consequences of an elevated plasma cystathionine concentration in adults with stable angina pectoris (SAP), we conducted both targeted and untargeted metabolomic analyses.Methods: We conducted NMR and LC-mass spectrometry (MS) metabolomic analyses on a subset of 80 plasma samples from the Western Norway Coronary Angiography Cohort and selected, based on plasma cystathionine concentrations, a group with high cystathionine concentrations [1.32 ± 0.60 µmol/L (mean ± SD); n = 40] and a group with low cystathionine concentrations [0.137 ± 0.011 µmol/L (mean ± SD); n = 40]. Targeted and untargeted metabolomic analyses were performed and assessed with the use of Student's t tests corrected for multiple testing. Overall differences between the cystathionine groups were assessed by untargeted NMR and LC-MS metabolomic methods and evaluated by partial least squares discriminant analysis (PLS-DA) with significant discriminating metabolites identified with 99% confidence.Results: Subjects with high cystathionine concentrations had 75% higher plasma lanthionine concentrations (0.12 ± 0.044 µmol/L) than subjects with low cystathionine concentrations [0.032 ± 0.013 µmol/L (P < 0.001)]. Although plasma homolanthionine concentrations were notably higher than lanthionine concentrations, they were not different between the groups (P = 0.47). PLS-DA results showed that a high plasma cystathionine concentration in SAP was associated with higher glucose, branched-chain amino acids, and phenylalanine concentrations, lower kidney function, and lower glutathione and plasma PLP concentrations due to greater catabolism. The high-cystathionine group had a greater proportion of subjects in the postprandial state.Conclusion: These data suggest that metabolic perturbations consistent with higher CVD risk exist in SAP patients with elevated plasma cystathionine concentrations.


Angina, Stable/etiology , Cystathionine/blood , Metabolic Networks and Pathways , Alanine/analogs & derivatives , Alanine/blood , Amino Acids, Branched-Chain/blood , Angina, Stable/blood , Blood Glucose/metabolism , Cardiovascular Diseases/blood , Cardiovascular Diseases/etiology , Female , Glutathione/blood , Homocysteine/blood , Humans , Hydrogen Sulfide/blood , Kidney/metabolism , Male , Mass Spectrometry , Metabolome , Middle Aged , Nutritional Status , Phenylalanine/blood , Pyridoxal Phosphate/blood , Risk , Sulfides/blood , Vitamin B Complex/blood , Vitamin B Deficiency/blood , Vitamin B Deficiency/complications
11.
Obes Surg ; 27(5): 1271-1276, 2017 05.
Article En | MEDLINE | ID: mdl-27889885

BACKGROUND: Laparoscopic sleeve gastrectomy (LSG) has gained popularity as the leading bariatric procedure for the treatment of morbid obesity. Due to the rising numbers of bariatric surgeries, neurologic complications have become increasingly recognized. Our aim was to examine biochemical and hormonal factors that are associated with neuropathy post-LSG. METHODS: Thirty-two patients were included: 16 patients with neuropathy in the neuropathic group (NG) and 16 patients without neuropathy in the control group (CG). Diagnosis was made by a consultant neurologist, and blood samples were taken to examine vitamin deficiencies and hormones involved in neuropathy. RESULTS: There was no significant difference between the BMI (p = 0.1) in both groups as well as excess weight loss percentages post-LSG at 12 months (p = 0.6). B12 levels were within normal range, but higher in NG (p = 0.005). Vitamin B1 and B2 levels were significantly lower in NG; p values are 0.000 and 0.031, respectively. Vitamin B6 levels were significantly higher in NG (p = 0.02) and copper levels were lower in NG (p = 0.009). There was no significant difference in GLP-1 response in both groups. CONCLUSION: Our data showed post-LSG neuropathy is associated with lower levels of vitamin B1, B2, and copper, plus patients who are older in age. Vitamin B6 was significantly higher in the NG, which is, at toxic levels, associated with neuropathy. No difference in preoperative BMI, excess weight loss percent at 1 year, and GLP-1 levels was found. Larger data is required to validate our results.


Copper/deficiency , Gastrectomy/adverse effects , Glucagon-Like Peptide 1/deficiency , Obesity, Morbid/surgery , Vitamin B Deficiency/blood , Adult , Copper/blood , Female , Glucagon-Like Peptide 1/blood , Humans , Laparoscopy , Male , Middle Aged , Treatment Outcome , Vitamin B Deficiency/etiology , Weight Loss
12.
J Clin Neuromuscul Dis ; 17(4): 212-4, 2016 Jun.
Article En | MEDLINE | ID: mdl-27224436

Abnormal concentrations of nutritional factors were found in 24.1% of 187 patients with neuropathy who were newly seen at our academic neuropathy referral center over a 1-year period. All patients presented with sensory axonal or small fiber neuropathy. In 7.3%, they were present in association with at least one other identifiable cause for neuropathy. Elevated levels of pyridoxal phosphate or mercury occurred more frequently than deficiencies in vitamins B1, B12, or B6. The nutritional abnormalities are amenable to correction by dietary intervention.


Mercury/blood , Peripheral Nervous System Diseases/complications , Pyridoxal Phosphate/blood , Small Fiber Neuropathy/complications , Vitamin B Deficiency/complications , Electronic Health Records , Humans , Peripheral Nervous System Diseases/blood , Small Fiber Neuropathy/blood , Vitamin B Deficiency/blood
13.
J Pediatr Gastroenterol Nutr ; 62(5): 746-50, 2016 05.
Article En | MEDLINE | ID: mdl-26655939

OBJECTIVES: Infants with biliary atresia (BA) are at high risk of vitamin D deficiency. We aimed to determine the prevalence and factors influencing vitamin D levels at presentation and post-Kasai portoenterostomy (KPE). METHODS: Single-centre retrospective review of infants with BA who underwent KPE. Pre- and postoperatively 25-hydroxyvitamin D (25-OHVD), liver and bone biochemistry data were collected. 25-OHVD levels <10 and 10 to 20 ng/mL were defined as vitamin D "deficiency" and "insufficiency," respectively. RESULTS: One hundred twenty-nine infants with BA (isolated n = 101, developmental n = 28, and white n = 79; non-white n = 50) were included in this study. At presentation, 75 of 92 (81%) were vitamin D deficient and only 1 infant had a level >20 ng/mL. Median 25-OHVD levels were 5(2-23), 17(2-72), 15(2-80), 17(2-69), and 23(2-98) ng/mL at pre-KPE, 1, 4, 6, and 12 months postoperation. There was no difference in 25-OHVD levels between the isolated and developmental groups with BA. Pre-KPE, white infants had significantly higher levels than non-white infants (6[2-23] vs 3[2-14] ng/mL, P = 0.01). Post-KPE 25-OHVD levels correlated well with liver and bone biochemical variables (eg, at 6 months: bilirubin rs = -0.34; P < 0.001, alkaline phosphatase rs = -0.46; P < 0.00001, and phosphate rs = 0.49; P < 0.00001). CONCLUSIONS: 25-OHVD deficiency is invariable at presentation in infants with BA, irrespective of its likely aetiology, and is more severe in non-white infants. Despite routine parenteral and enteral supplementation, low 25-OHVD levels persist post KPE especially in icteric infants. More aggressive vitamin D supplementation and monitoring in this population is paramount.


Biliary Atresia/surgery , Vitamin B Deficiency/epidemiology , Vitamin D/blood , Biliary Atresia/blood , Biliary Atresia/complications , Bone Density , Female , Humans , Infant , Infant Nutritional Physiological Phenomena , Infant, Newborn , London/epidemiology , Male , Portoenterostomy, Hepatic , Postoperative Period , Preoperative Period , Prevalence , Retrospective Studies , Vitamin B Deficiency/blood , Vitamin B Deficiency/complications
14.
Nutrients ; 7(9): 7781-97, 2015 Sep 14.
Article En | MEDLINE | ID: mdl-26389945

Low vitamin B-12 concentrations are frequently observed among older adults. Malabsorption is hypothesized to be an important cause of vitamin B-12 inadequacy, but serum vitamin B-12 may also be differently affected by vitamin B-12 intake depending on food source. We examined associations between dietary sources of vitamin B-12 (meat, fish and shellfish, eggs, dairy) and serum vitamin B-12, using cross-sectional data of 600 Dutch community-dwelling adults (≥65 years). Dietary intake was assessed with a validated food frequency questionnaire. Vitamin B-12 concentrations were measured in serum. Associations were studied over tertiles of vitamin B-12 intake using P for trend, by calculating prevalence ratios (PRs), and splines. Whereas men had significantly higher vitamin B-12 intakes than women (median (25th-75th percentile): 4.18 (3.29-5.38) versus 3.47 (2.64-4.40) µg/day), serum vitamin B-12 did not differ between the two sexes (mean ± standard deviation (SD): 275 ± 104 pmol/L versus 290 ± 113 pmol/L). Higher intakes of dairy, meat, and fish and shellfish were significantly associated with higher serum vitamin B-12 concentrations, where meat and dairy-predominantly milk were the most potent sources. Egg intake did not significantly contribute to higher serum vitamin B-12 concentrations. Thus, dairy and meat were the most important contributors to serum vitamin B-12, followed by fish and shellfish.


Diet , Nutritional Status , Vitamin B 12/blood , Vitamin B Deficiency/blood , Age Factors , Aged , Aging/blood , Animals , Biomarkers/blood , Cross-Sectional Studies , Dairy Products , Eggs , Female , Fishes , Humans , Male , Meat , Netherlands/epidemiology , Nutrition Assessment , Prevalence , Seafood , Sex Factors , Shellfish , Surveys and Questionnaires , Vitamin B Deficiency/diagnosis , Vitamin B Deficiency/epidemiology , Vitamin B Deficiency/prevention & control
15.
J Clin Res Pediatr Endocrinol ; 7(2): 128-33, 2015 Jun.
Article En | MEDLINE | ID: mdl-26316435

OBJECTIVE: Vitamin D has been suggested to be active as an immunomodulator in autoimmune diseases such as Hashimoto's thyroiditis (HT). The goal of the present study was to investigate the vitamin D status in HT patients. METHODS: This prevalence case-control study was conducted on 90 patients with HT (of ages 12.32 ± 2.87 years) and 79 age-matched healthy controls (11.85 ± 2.28 years). Serum 25-hydroxyvitamin D3 [25(OH)D3] levels were measured in all 169 subjects. RESULTS: The prevalence of vitamin D deficiency in HT patients (64 of 90; 71.1%) was significantly higher than that in the control group (41 of 79; 51.9%) (p=0.025). Mean serum 25(OH)D3 level in the HT group was significantly lower compared to the control group (16.67 ± 11.65 vs. 20.99 ± 9.86 ng/mL, p=0.001). HT was observed 2.28 times more frequently in individuals with 25(OH)D3 levels <20 ng/mL (OR: 2.28, CI: 1.21-4.3). CONCLUSION: Vitamin D deficiency is associated with HT in children and adolescents. Levels lower than 20 ng/mL seem to be critical. The mechanism for this association is not clear.


Hashimoto Disease/complications , Vitamin B Deficiency/complications , Vitamin D/blood , Adolescent , Calcifediol/blood , Case-Control Studies , Child , Child, Preschool , Female , Hashimoto Disease/blood , Hashimoto Disease/epidemiology , Humans , Male , Prevalence , Thyroid Function Tests , Vitamin B Deficiency/blood , Vitamin B Deficiency/epidemiology , Vitamin D Deficiency/epidemiology
16.
BJOG ; 122(12): 1586-92, 2015 Nov.
Article En | MEDLINE | ID: mdl-26213116

OBJECTIVE: To evaluate the usefulness of serial determinations of asymmetric dimethylarginine (ADMA) and homocysteine (Hcy) concentrations during pregnancy to predict pre-eclampsia, taking into account maternal obesity and B vitamin status. DESIGN: Longitudinal study. SETTING: Two obstetric referral hospitals. SAMPLE: Two hundred and fifty-two of 411 women invited to participate in the study. METHODS: The women made monthly visits from ≤20 weeks of gestation until delivery for measurements of plasma ADMA, Hcy, and vitamins B6 , B12, and folic acid, and for the recording of clinical information. MAIN OUTCOME MEASURE: Early elevations in plasma ADMA and Hcy related to the development of pre-eclampsia. RESULTS: Of the 252 women who completed the study, 179 had no complications, 49 developed pre-eclampsia, and 24 presented with complications other than pre-eclampsia. ADMA and Hcy increased gradually throughout pregnancy in the pre-eclampsia group, independent of maternal B-vitamin status and obesity, but remained constant in women with no complications. Relative to the preceding month, ADMA and Hcy levels increased 1 month prior to the onset of pre-eclampsia: 124 ± 27 nmol (P < 0.001) and 1177 ± 278 nmol (P = 0.001), respectively, in the pre-eclampsia group. The group of women with no complications did not show any significant changes. Increases of 80 nmol ADMA and 1000 nmol Hcy at 1 month prior to the onset of pre-eclampsia demonstrated the best potential for prediction. CONCLUSIONS: Increased ADMA and Hcy levels precede clinical manifestations of pre-eclampsia. Therefore, serial determinations of their concentrations may be helpful in identifying women at risk. TWEETABLE ABSTRACT: Increased ADMA and Hcy precede clinical pre-eclampsia and may identify women at risk.


Arginine/analogs & derivatives , Folic Acid/blood , Homocysteine/blood , Pre-Eclampsia/blood , Pre-Eclampsia/diagnosis , Vitamin B Complex/blood , Vitamin B Deficiency/blood , Adult , Arginine/blood , Biomarkers/blood , Body Mass Index , Female , Follow-Up Studies , Humans , Longitudinal Studies , Pre-Eclampsia/epidemiology , Predictive Value of Tests , Pregnancy , Risk Factors , United Kingdom/epidemiology , Vitamin B Deficiency/epidemiology
17.
J Hepatol ; 63(5): 1086-92, 2015 Nov.
Article En | MEDLINE | ID: mdl-26143444

BACKGROUND & AIMS: The relationship between vitamin D levels and chronic hepatitis B (CHB) infection and treatment outcomes are poorly elucidated. We measured pre-treatment serum vitamin D (25-hydroxyvitamin D3; 25[OH]D3) levels and determined their association with clinical parameters and treatment outcomes in active CHB patients without advanced liver disease enrolled in a global clinical trial. METHODS: Patients were randomly assigned to either 48 weeks of tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2a (PegIFN), TDF plus PegIFN for 16 weeks followed by TDF for 32 weeks, PegIFN for 48 weeks, or TDF for 120 weeks. Univariate and multivariate analyses were conducted to determine associations between vitamin D, baseline factors, and week 48 clinical outcome. RESULTS: Of 737 patients, 35% had insufficient (⩾20 but <31 ng/ml) and 58% had deficient (<20 ng/ml) vitamin D levels. In univariate analysis, lower vitamin D levels were significantly associated with the following baseline parameters: younger age, lower uric acid levels, HBeAg-positive status, lower calcium levels, blood draw in winter or autumn, and HBV genotype D. On multivariate analysis, only HBV genotype, season of blood draw, calcium level, and age retained their association. High baseline level of vitamin D was associated with low HBV DNA, normal ALT and HBsAg at week 48 independent of treatment groups, but the association, with the exception of ALT, became statistically insignificant after adjusting for age, gender, HBeAg and HBV genotype. CONCLUSIONS: Abnormally low vitamin D levels are highly prevalent among untreated, active CHB patients. Baseline vitamin D levels are not associated with treatment outcomes, but were associated with normal ALT.


Hepatitis B, Chronic/drug therapy , Interferon-alpha/therapeutic use , Polyethylene Glycols/therapeutic use , Tenofovir/therapeutic use , Vitamin B Deficiency/blood , Vitamin D/pharmacokinetics , Adolescent , Adult , Aged , Antiviral Agents/therapeutic use , Biomarkers/blood , DNA, Viral/analysis , Drug Carriers , Drug Therapy, Combination , Female , Follow-Up Studies , Hepatitis B virus/genetics , Hepatitis B, Chronic/complications , Hepatitis B, Chronic/virology , Humans , Male , Middle Aged , Recombinant Proteins/therapeutic use , Time Factors , Treatment Outcome , Vitamin B Deficiency/drug therapy , Vitamin B Deficiency/etiology , Vitamins/pharmacokinetics , Young Adult
18.
Basic Clin Pharmacol Toxicol ; 117(5): 287-96, 2015 Nov.
Article En | MEDLINE | ID: mdl-26036286

Neurodegenerative diseases are the diseases of the central nervous system with various aetiology and symptoms. Dementia, Alzheimer's disease (AD), Parkinson's disease (PD) and autism are some examples of neurodegenerative diseases. Hyperhomocysteinemia (Hhcy) is considered to be an independent risk factor for numerous pathological conditions under neurodegenerative diseases. Along with genetic factors that are the prime cause of homocysteine (Hcy) imbalance, the nutritional and hormonal factors are also contributing to high Hcy levels in the body. Numerous clinical and epidemiological data confirm the direct correlation of Hcy levels in the body and generation of different types of central nervous system disorders, cardiovascular diseases, cancer and others. Till now, it is difficult to say whether homocysteine is the cause of the disease or whether it is one of the impacts of the diseases. However, Hhcy is a surrogate marker of vitamin B deficiency and is a neurotoxic agent. This Mini Review will give an overview of how far research has gone into understanding the homocysteine imbalance with prognostic, causative and preventive measures in treating neurodegenerative diseases.


Homocysteine/blood , Hyperhomocysteinemia , Neurodegenerative Diseases , Animals , Biomarkers/blood , Humans , Hyperhomocysteinemia/blood , Hyperhomocysteinemia/diagnosis , Hyperhomocysteinemia/epidemiology , Hyperhomocysteinemia/therapy , Neurodegenerative Diseases/blood , Neurodegenerative Diseases/diagnosis , Neurodegenerative Diseases/epidemiology , Neurodegenerative Diseases/therapy , Nutritional Status , Prognosis , Risk Factors , Vitamin B Deficiency/blood , Vitamin B Deficiency/epidemiology
19.
Nutrients ; 7(4): 2518-23, 2015 Apr 08.
Article En | MEDLINE | ID: mdl-25856222

Micronutrient deficiency conditions are a major global public health problem. While the private sector has an important role in addressing this problem, the main responsibility lies with national governments, in cooperation with international agencies and donors. Mandatory fortification of basic foods provides a basic necessary intake for the majority and needs to be supported by provision of essential vitamin and mineral supplements for mothers and children and other high risk groups. Fortification by government mandate and regulation is essential with cooperation by private sector food manufacturers, and in the context of broader policies for poverty reduction, education and agricultural reform. Iron, iodine, vitamin A, vitamin B complex, folic acid, zinc, vitamin D and vitamin B12 are prime examples of international fortification experience achieved by proactive governmental nutrition policies. These are essential to achieve the Millennium Development Goals and their follow-up sustainable global health targets. National governmental policies for nutritional security and initiatives are essential to implement both food fortification and targeted supplementation policies to reduce the huge burden of micronutrient deficiency conditions in Southeast Asia and other parts of the world.


Malnutrition/epidemiology , Micronutrients/deficiency , Nutrition Policy/legislation & jurisprudence , Pandemics , Asia, Southeastern/epidemiology , Dietary Supplements , Folic Acid Deficiency/blood , Folic Acid Deficiency/drug therapy , Folic Acid Deficiency/epidemiology , Food, Fortified , Humans , Iodine/administration & dosage , Iodine/blood , Iodine/deficiency , Iron/administration & dosage , Iron/blood , Iron Deficiencies , Malnutrition/drug therapy , Micronutrients/administration & dosage , Public Health , Vitamin A/administration & dosage , Vitamin A/blood , Vitamin A Deficiency/blood , Vitamin A Deficiency/drug therapy , Vitamin A Deficiency/epidemiology , Vitamin B 12 Deficiency/blood , Vitamin B 12 Deficiency/drug therapy , Vitamin B 12 Deficiency/epidemiology , Vitamin B Deficiency/blood , Vitamin B Deficiency/drug therapy , Vitamin B Deficiency/epidemiology , Vitamin D Deficiency/blood , Vitamin D Deficiency/drug therapy , Vitamin D Deficiency/epidemiology , Zinc/administration & dosage , Zinc/blood , Zinc/deficiency
20.
Curr Opin Clin Nutr Metab Care ; 18(3): 295-306, 2015 May.
Article En | MEDLINE | ID: mdl-25807352

PURPOSE OF REVIEW: This review examines the effect of B vitamins on women and child health from recent evidence available. RECENT FINDINGS: Findings were related to functional outcomes. In terms of foetal growth, although supplementation with B12 increased B12 status of nonpregnant and pregnant women and infants, maternal plasma homocysteine, which is related to multiple deficiencies of vitamin B12, B6, riboflavin or folate, has been shown to be associated with lower birth size rather than solely plasma B12. However, an experimental study with thiamine supplementation showed improvement in status in thiamine-deficient mothers and breast milk concentration, but not in infant status. Given the multiple aetiology of anaemia, the use of multiple micronutrient fortification has expectedly shown a reduction in anaemia prevalence in women. Furthermore, these micronutrients can interact with each other: high maternal folate intakes coupled with low B12 intakes were associated with a higher risk of delivering a small-for-gestational age infant. A high maternal plasma folate was also associated with insulin resistance in children aged 9.5 and 13.5 years. SUMMARY: Interventions with B vitamins were found to be efficacious in improving the status in women and children. In multiple micronutrient supplementation programmes, the optimum composition of the supplement needs to be determined. The deleterious effect of high folate intakes with low B12 intakes needs to be explored further.


Dietary Supplements , Maternal Nutritional Physiological Phenomena , Nutritional Status , Poverty , Pregnancy Complications/drug therapy , Vitamin B Complex/therapeutic use , Vitamin B Deficiency/drug therapy , Child , Child Health , Female , Humans , Pregnancy , Pregnancy Complications/blood , Vitamin B Complex/blood , Vitamin B Deficiency/blood , Vitamin B Deficiency/complications , Women's Health
...